News Update

CJI sets up two Benches to speed up income tax casesEgyptian President likely to be India’s guest at next Republic Day ParadeVeteran actor Vikram Gokhale passes away at 77ED files charge-sheet in liquor scam caseTax fraud case: Shakira flays Spanish revenue authoritiesGST - Entertainment of writ petition at the stage of notice would be premature - Doing so would frustrate the tax administration and interdict adjudication process: HCNight Sky Sanctuary in Ladakh to be ready in one monthGST - Cancellation of registration - Maintainability of Petition without exhausting appellate remedy - Petition disposed of by leaving it open to petitioner to approach appellate authority within one week: HCMoS inaugurates Digital India Startup Hub at STPI in KarnatakaVAT - If period of limitation is enlarged from 5 years to 6 years, then dealer does not have vested right or accrued interest vis-a-vis reassessment procedure u/s 25 of KVAT Act: HCMinister presents India's approach on combating Anti-Microbial Resistance at Global MeetFM chairs Pre-Budget consultation with State FMsCX - Rule 3(5A) of CCR 2004 - Interpretation of term Removal has been held to mean physical movement of goods from one place to another: CESTATCBIC amends Customs rates on Flat Panel Display ModulesCX - When there is no removal of capital goods, provisions of Rule 3(5A) of CCR 2004 cannot be invoked: CESTATGovt appoints Shri Harsuhinder Pal Singh Brar as Additional Commissioner, Excise and Taxation Department, Union territory of ChandigarhI-T- PCIT must provide cogent evidence to prove excercise of jurisdiction u/s 263 : ITATModification in Standard Input Output Norms (SION) of Textiles (Product Code 'J'): Amendment in SION J-222I-T- Disallowance u/s 36(1)(ii) is eligible only for employees who are partners or shareholders : ITATGST Council to hold 48th meeting virtually on Dec 17, 2022iPhone Nov shipments clobbered hard after mess at Foxconn’s China plantAmerica bans ZTE & Huawei equipments on security ground
 
WHO product alert on cough syrup - Probe rolled out

By TIOL News Service

NEW DELHI, OCT 07, 2022: WHO on 29.09.2022 informed DCGI, the National Drug Regulator of India, that WHO it is currently providing technical assistance and advice to Gambia, where children have died and where a contributing factor, is suspected to be the use of medicines which may have been contaminated with Diethylene glycol or Ethylene glycol (in some of the samples it was claimed to have been confirmed by further analysis conducted by WHO).

CDSCO took up the matter immediately with Haryana State Regulatory Authority, under whose jurisdiction the drug manufacturing unit of M/s Maiden Pharmaceutical Limited, Sonepat is located. Further, a detailed investigation was launched to ascertain the facts/ details in the matter in collaboration with State Drugs Controller, Haryana.

From the preliminary enquiry of CDSCO, it has been made out that M/s Maiden Pharmaceutical Limited, Sonepat, Haryana is a manufacturer licensed by the State Drug Controller for the products Promethazine Oral Solution BP, Kofexnalin Baby Cough Syrup, MaKoff Baby Cough Syrup and MaGrip n Cold Syrup under reference, and holds manufacturing permission for these products for export only. The company has manufactured and exported these products only to Gambia.

It is a usual practice that the importing country tests these imported products on quality parameters, and satisfies itself as to the quality of the products before the importing country decides to release such products for usage in the country.

As per the tentative results received by WHO, out of the 23 samples of the products under reference which were tested, 04 samples have been found to contain Diethylene Glycol/ Ethylene Glycol. It has also been informed by WHO that the certificate of analysis will be made available to WHO in near future and WHO will share it with the Indian Regulator which is yet to be done. The exact one to one causal relation of death has not yet been provided by WHO to CDSCO.

As a robust National Regulatory Authority, CDSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.

The State Drug Controller had given licenses to the said Company only for export of these four drugs namely Promethazine Oral Solution BP, Kofexnalin Baby Cough Syrup, MaKoff Baby Cough Syrup and MaGrip n Cold Syrup. Further all these 04 drugs manufactured only for exports by M/s. Maiden Pharmaceuticals Limited are not licensed for manufacture and sale in India. In effect, none of these four drugs of M/s. Maiden Pharmaceuticals is sold domestically in India.

The samples (controlled samples of the same batch manufactured by M/s. Maiden Pharmaceuticals Limited for all the four drugs in question) have been taken and sent for testing to Regional Drug Testing Lab, Chandigarh by CDSCO, the results of which will guide further course of action as well as bring clarity on the inputs received/ to be received from WHO.


POST YOUR COMMENTS